| Orencia (abatacept) / BMS |
NCT01717846: Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis |
|
|
| Withdrawn | 4 | 0 | US | Group 1 or Orencia treated group, Abatacept, Group 2 (DMARDS treated group), Arm 2 or group 2 | University of California, Los Angeles, Bristol-Myers Squibb | Apoptotic DNA Damage, Rheumatoid Arthritis, T-cell Lymphocytosis | 11/13 | 11/14 | | |
A-BREAK, NCT01846975: Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday |
|
|
| Completed | 4 | 49 | Europe | IV Abatacept, Switch from SC to IV Abatacept and back | Rüdiger B. Müller, Bristol-Myers Squibb | Rheumatoid Arthritis | 12/14 | 01/15 | | |
| Completed | 4 | 122 | Europe | Etanercept, Abatacept, Rituximab, Adalimumab, Certolizumab Pegol, Infliximab, Golimumab | Julia Brown | Rheumatoid Arthritis | 11/15 | 11/15 | | |
|
NCT01758198: Abatacept Post-marketing Clinical Study in Japan |
|
|
| Completed | 4 | 405 | Japan | Abatacept, BMS-188667 (Orencia), Placebo matching with Abatacept, Methotrexate | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Rheumatoid Arthritis | 12/16 | 12/16 | | |
NCT01638715 / 2012-000139-21: A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action |
|
|
| Completed | 4 | 115 | Europe, RoW | Remicade, Orencia, Ro-Actemra, Mabthera | Medical University of Vienna | Rheumatoid Arthritis | 08/18 | 08/18 | | |
